Cardiome Pharma Corp. To Present RSD1235 Abstract At American Heart Association

VANCOUVER, Nov. 10 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. today announced that an abstract on its lead antiarrhythmic drug, RSD1235, is scheduled to be presented at the American Heart Association Scientific Sessions meeting to be held in Dallas from November 13-16, 2005.

A Phase 2B clinical trial in patients undergoing electrophysiologic study will be presented by Dr. Paul Dorian of St. Michael's Hospital, Toronto, Ontario at 4:30pm Dallas time (2:30pm PST) on November 14, 2005. The presentation is entitled "The Investigational Antiarrhythmic Agent RSD1235 is Atrially Selective in Humans."

The study involved two groups exposed to two different therapeutic dose levels of RSD1235, and the findings support the atrial specific activity of RSD1235 in humans.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with three clinical drug programs, two of which focus on atrial arrhythmia (intravenous and oral dosing) and one directed at congestive heart failure.

RSD1235 IV is the intravenous formulation of an investigational drug being evaluated for the acute treatment of recent-onset atrial fibrillation (AF). Positive top-line results from two Phase 3 trials for RSD1235 IV, called ACT 1 and ACT 3, were released in December 2004 and September 2005. The ACT 2 study, evaluating patients with post-operative atrial arrhythmia, is ongoing. RSD1235 is also being investigated as a chronic-use oral drug for the maintenance of normal heart rhythm following termination of AF.

Cardiome recently completed a Phase 2 clinical trial evaluating the safety and effectiveness of oxypurinol, a xanthine oxidase inhibitor, for the treatment of congestive heart failure (CHF). Top-line results from this trial were negative. Cardiome is in the process of analyzing the entire data package from the trial prior to making any decision regarding the program.

Cardiome recently completed the acquisition of Artesian Therapeutics Inc., a privately held U.S. biopharmaceutical company developing bi-functional small-molecule drugs for the treatment of cardiovascular disease.

Cardiome is traded on the Toronto Stock Exchange (COM) and the NASDAQ National Market (CRME). Further information about Cardiome can be found at www.cardiome.com.

For Further Information: Don Graham Peter K. Hofman Director of Corporate Communication Director of Investor Relations (604) 676-6963 or (604) 676-6993 Toll Free: 1-800-330-9928 Email: dgraham@cardiome.com Email: phofman@cardiome.com Forward-Looking Statement Disclaimer

Statements contained in this news release relating to future results, events and expectation are forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such statements. Such factors include, among others, those described in the Company's annual report on Form 40-F. The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

CONTACT: Don Graham, Director of Corporate Communication, (604) 676-6963or Toll Free: 1-800-330-9928, Email: dgraham@cardiome.com; Peter K. Hofman,Director of Investor Relations, (604) 676-6993, Email: phofman@cardiome.com